Mei Ri Jing Ji Xin Wen·2025-05-07 11:36Group 1 - The core point of the news is that Haohai Biological Technology (688366.SH) announced that its controlling shareholder, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading, which is unrelated to the company's stock [1] - The investigation pertains solely to Jiang Wei as an individual and will not significantly impact the company's daily operations [1] - As of May 7, Haohai Biological's stock price was 53.17 yuan, with a market capitalization of 12.399 billion yuan [1] Group 2 - Haohai Biological is a technology innovation company focused on the research, production, and sales of medical devices and pharmaceuticals using biomedical materials and genetic engineering technology [3] - The company aims to provide innovative medical products through technological innovation and resource integration, gradually achieving import substitution in related pharmaceutical products [3] - As of 2023, Haohai Biological has completed industry restructuring in biomedical materials and has achieved leading advantages in four main business areas: ophthalmology, plastic surgery and wound care, orthopedics, and anti-adhesion and hemostasis [3] Group 3 - For Q1 2025, Haohai Biological reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.3121 million yuan, down 7.41% year-on-year [3] - The company's basic earnings per share for the first quarter were 0.39 yuan [3] - As of May 7, the stock price of Haohai Biological had decreased by 0.21% [4]